Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma
NCT02455557Phase 2Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- May 2015
- Primary completion
- Oct 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SurVaxM in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Roswell Park Comprehensive Cancer Center. Started May 2015; status: active, not recruiting.
02
Drugs
SurVaxM
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02455557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02455557.